Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is a prospective, open label, parallel controlled study to evaluate the efficacy and safety of neoadjuvant pyrotinib in HER2+ breast cancer patients
Epistemonikos ID: 0e8efe0aafdd41301f331525dcfc1100e80d189a
First added on: May 07, 2024